Phase II study of ET-743 in advanced soft tissue sarcomas: A European Organisation for the Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group trial

Journal of Clinical Oncology

Volumn 23, Issue 3, 2005, Pages 576-584

  Blay, J Y ^a   Judson, I ^a   Van Oosterom, A ^a   Verweij, J ^a   Radford, J ^a   Lorigan, P ^a   Rodenhuis, S ^a   Ray Coquard, I ^a   Bonvalot, S ^a   Collin, F ^a   Jimeno, J ^a   Di Paola, E ^a   Van Glabbeke, M ^a   Nielsen, O S ^a   Cesne, Axel Le ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; DOXORUBICIN; GRANISETRON; IFOSFAMIDE; METOCLOPRAMIDE; ONDANSETRON; TRABECTEDIN; 1,3 DIOXOLANE DERIVATIVE; ALKYLATING AGENT; ISOQUINOLINE DERIVATIVE; TETRAHYDROISOQUINOLINE DERIVATIVE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ALOPECIA; ANEMIA; ANGIOSARCOMA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BLOOD TOXICITY; CARDIOTOXICITY; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DISEASE COURSE; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG ACTIVITY; DRUG DOSE REDUCTION; DRUG MECHANISM; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FIBROSARCOMA; HUMAN; LEIOMYOSARCOMA; LIPOSARCOMA; LIVER DYSFUNCTION; LIVER TOXICITY; MALE; MALIGNANT FIBROUS HISTIOCYTOMA; MALIGNANT NEURINOMA; MULTICENTER STUDY; MULTIPLE ORGAN FAILURE; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RHABDOMYOSARCOMA; SEPTIC SHOCK; SIDE EFFECT; SOFT TISSUE SARCOMA; SURVIVAL TIME; SYNOVIAL SARCOMA; THROMBOCYTOPENIA; TREATMENT RESPONSE; UNDIFFERENTIATED CARCINOMA; VOMITING; ADOLESCENT; DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; SARCOMA; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, ALKYLATING; DIOXOLES; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; ISOQUINOLINES; MALE; MIDDLE AGED; SARCOMA; TETRAHYDROISOQUINOLINES; TREATMENT OUTCOME;

EID: 20044372153     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.01.180     Document Type: Article

References (42)

1. Nielsen O, Blay JY, Judson IR, et al: Metastatic soft tissue sarcoma in adults: Prognosis and treatment options. Am J Cancer 2:211-221, 2003
2. Nielsen O, Dombernowsky P, Mouridsen H, et al: High dose epirubicin is not an alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas: A study of the EORTC Soft Tissue and Bone Sarcoma Group. Br J Cancer 78:1634-1639, 1998
3. Judson I, Ratford JA, Harris M, et al: Randomized phase II trial of pegylated liposomal doxorubicin (Doxil/Caelyx) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: A study by the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 37:870-877, 2001
4. Lorigan PC, Verweij J, Papai Z, et al: Randomized phase III trial of two investigational schedules of ifosfamide versus standard dose doxorubicin in patients with advanced or metastatic soft tissue sarcoma. Proc Am Soc Clin Oncol 21:353a, 2002 (abstr 1616)
5. Verweij J, Van Glabbeke M: Translating targets into treatment: Changes in trial methodology and treatment approaches for soft tissue sarcomas, in New Approaches to Assessment, Classification and Treatment of Soft Tissue Sarcomas Educational Book. Alexandria, VA, American Society of Clinical Oncology, 2003, pp 522-530
6. Guan Y, Sakai R, Rinehart KL, et al: Molecular and crystal structures of ecteinascidins: Potent antitumor compounds from the Caribbean tunicate Ecteinascidia turbinata. J Biomol Struct Dyn 10:793-818, 1993
7. Zewail-Foote M, Hurley LH: Ecteinascidin 743: A minor groove alkylator that bends DNA toward the major groove. J Med Chem 42:2493-2497, 1999
8. Erba E, Bergamaschi D, Bassano L, et al: Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action. Eur J Cancer 37:97-105, 2001
9. Gajate C, Feiyun A, Mollinedo F: Differential cytostatic and apoptotic effects of ecteinascidin-743 in cancer cells: Transcription-dependent cell cycle arrest and transcription-independent JNK and mitochondrial-mediated apoptosis. J Biol Chem 277:41580-41589, 2002
10. Izbicka E, Lawrence R, Raymond E, et al: In vitro antitumor activity of the novel marine agent, ecteinascidin-743 (ET-743, NSC-648766) against human tumors explanted from patients. Ann Oncol 9:981-987, 1998
11. Jimeno JM, Faircloth G, Cameron L, et al: Progress in the acquisition of new marine-derived anticancer compounds: Development of ecteinascidin-743 (ET-743). Drugs Future 21: 1155-1165, 1996
12. Twelves C, Hoekman K, Bowman A, et al.: Phase I and pharmacokinetic study of Yondelis (Ecteinascidin 743; ET-743) administered as an infusion over 1h or 3h every 21 days in patients with solid tumors. Eur J Cancer 39:1842-1851, 2003
13. Taamma A, Misset JL, Riofrio M, et al: Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors. J Clin Oncol 19:1256-1265, 2001
14. Ryan DP, Supko JG, Eder JP, et al: Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies. Clin Cancer Res 7:231-242, 2001
15. Villalona-Calero MA, Eckhardt SG, Weiss G, et al: A phase I and pharmacokinetic study of ecteinascidin-743 on a daily x 5 schedule in patients with solid malignancies. Clin Cancer Res 8:75-85, 2002
16. Forouzeh B, Hildago M, Denis L, et al: Phase I and pharmacokinetic study of ET-743, a minor groove DNA binder administered weekly to patients with advanced cancer. Proc Am Soc Clin Oncol 20:94a, 2001 (373 abstr)
17. World Health Organization: WHO Handbook for reporting the results of cancer treatment. Geneva, Switzerland, WHO Offset Publication, 1979, p 48
18. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205-216, 2000
19. Blay JY, Van Glabbeke M, Verweij J, et al: Advanced soft-tissue sarcoma: A disease that is potentially curable for a subset of patients treated with chemotherapy. Eur J Cancer 39:64-69, 2003
20. Le Cesne A, Antoine E, Spielmann M, et al: High-dose ifosfamide: Circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas. J Clin Oncol 13:1600-1608, 1995
21. Nielsen OS, Judson I, Van Hoesel Q, et al: Effect of high-dose ifosfamide in advanced soft tissue sarcomas: A multicentre phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 36:61-67, 2000
22. Delaloge S, Yovine A, Taamma A, et al: Ecteinascidin-743: A marine-derived compound in advanced, pretreated sarcoma patients-preliminary evidence of activity. J Clin Oncol 19:1248-1255, 2001
23. Verweij J, Lee SM, Ruka W, et al: Randomized phase II study of Docetaxel versus doxorubicin in first and second line chemotherapy for locally advanced or metastatic soft tissue sarcomas in adult: A study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 18:2081-2086, 2000
24. Gomez J, Lopez-Lazaro L, Guzman C, et al.: Identification of biochemical parameters that predict the onset of severe toxicities in patients treated with ET-743. Pro Am Soc Clin Oncol 19:187, 2000
25. Lopez-Martin JA, Nieto A, Demetri GD, et al: Safety profile of ecteinascidin-743 (ET-743) in phase II clinical trials (CT) in adult patients with solid tumors. Proc Am Soc Clin Oncol 21:96a, 2002 (abstr 382)
26. Kanzaki A, Takebayashi Y, Ren XQ, et al: Overcoming multidrug drug resistance in P-glycoprotein/MDR1-overexpressing cell lines by ecteinascidin 743. Mol Cancer Ther 1:1327-1334, 2002
27. Le Cesne A, Misset JL, Demetri G, et al: Consistent evidence of activity of ecteinascidin (ET-743) in pretreated advanced soft-tissue sarcoma: Results from a pooled analysis of phase II clinical trials. Proc ECCO 37:534, 2001 (suppl)
28. Lopez-Martin JA, Verweij J, Blay J, et al: An exploratory analysis of tumor growth rate (TGR) variations induced by trabectedin (ecteinascidin-743) in patients with pretreated advanced soft tissue sarcoma. Proc Am Soc Clin Oncol 22:819, 2003 (abstr 3293)
29. Le Cesne A, Judson I, Crowther D, et al: Randomized phase III study comparing conventional dose doxorubicin plu ifosfamide versus high dose doxorubicin plus ifosfamide plus rh GM-CSF in advanced soft tissue sarcomas: An EORTC Soft Tissue and Bone Sarcoma Group trial. J Clin Oncol 18:2676-2684, 2000
30. Van Glabbeke M, Verweij J, Judson I, et al: Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas. Eur J Cancer 38:543-549, 2002
31. van Oosterom AT, Mouridsen HT, Nielsen OS, et al: Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients. Eur J Cancer 38:2397-2406, 2002
32. Hensley ML, Maki R, Venkatraman E, et al: Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: Results of a phase II trial. J Clin Oncol 20:2824-2831, 2002
33. Svancarova L, Blay JY, Judson IR, et al: Gemcitabine in advanced soft tissue sarcoma: A phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 38:556-559, 2002
34. Borden E, Baker L, Bell R, et al: Soft tissue sarcomas of adults: State of the translational science. Clin Cancer Res 9:1941-1956, 2003
35. Van Oosterom A, Judson I, Verweij J, et al: Safety and efficacy of Imatimib (STI-571) in metastatic gastrointestinal stromal tumors: A phase I study. Lancet 358:1421-1423, 2001
36. Demetri G, Von Mehren M, Blanke CD, et al: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347:472-480, 2002
37. Van Glabbeke M, Van Oosterom A, Oosterhuis JW, et al: Pronostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: An analysis of 2185 patients treated with anthracycline-containing first-line regimens-A European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol 17:150-157, 1999
38. Rosen G, Forscher C, Lowenbraun S, et al: Synovial sarcoma: Uniform response of metastases to high dose ifosfamide. Cancer 73:2506-2511, 1994
39. Fata F, O'Reilly E, Ilson D, et al: Paclitaxel in the treatment of patients with angiosarcoma of the scalp of face. Cancer 86:2034-2037, 1999
40. Merimsky O, Meller I, Flusser G, et al: Gemcitabine in soft tissue or bone sarcoma resistant to standard chemotherapy: A phase II study. Cancer Chemother Pharmacol 45:177-181, 2000
41. Demetri GD, Manola J, Harmon D et al: Ecteinascidin-743 (ET-743) induces durable responses and promising 1-year survival rates in soft tissue sarcomas (STS): Final results of phase II and pharmacokinetic studies in the USA. Proc Am Soc Clin Oncol 20:352a, 2001 (abstr 1406)
42. Gianni L, Grasselli F, De Braud P, et al: Definition of the last toxic sequence and optimal therapeutic dose of Yondelis in combination with doxorubicin in patients with untreated metastatic soft tissue sarcoma and advanced pretreated anthracyclines naive patients. Proc AACR/NC1/ EORTC Int Conf Molecular Targets Cancer Therapeutics 61:47a, 2003